Search peptides, terms, sources/
Research source · 2021

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

About this source

Kind
Research
Design
Human clinical trial, RCT
Population
Adults with overweight/obesity, without diabetes; 57 sites, 10 countries (Canada, Denmark, Finland, Ireland, Japan, Poland, Serbia, South Africa, UK, USA)
Sample size
706 randomised (about 100 per cagrilintide dose group, 99 liraglutide, 101 placebo)
Primary or secondary
primary
Peer review
peer reviewed
Retraction status
None known
Date checked
14 August 2026

Limitations

Sponsor-funded (Novo Nordisk); phase 2, not yet independently replicated as a standalone-agent trial.

Cited in

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.